For cost-effective, streamlined, targeted next-generation sequencing (NGS) of specific genetic diseases or conditions, Illumina offers TruSight sequencing panels. Designed with recognized healthcare experts at leading institutions, TruSight panels comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.
Each TruSight sequencing panel offers:
- Streamlined Workflow
Pre-designed, expert-selected content and use of proven Illumina NGS technology reduce assay optimization time and risk of manual error
- Accurate Results
Deep uniform coverage enables highly accurate variant calling suitable for the clinical genomics laboratory
- Increased Productivity
Product lot testing, extended shelf life, and single-lot shipments keep your lab running while reducing costs; TruSight One Sequencing Panel is able to replace multiple genetic assays
TruSight Tumor 170
Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression
TruSight RNA Fusion
Targeting 507 fusion associated genes in cancer; detects known and novel fusion gene partners.
Targeting > 4,800 genes; enabling labs to expand and streamline their assay portfolio and sequencing portfolio
Accurate, unambiguous, phase-resolved HLA typing in a single assay
TruSight RNA Pan-Cancer
Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE
Uses expert-defined content to identify somatic mutations in myeloid malignancies
Targeting genes previously linked to a predisposition towards cancer
TruSight Tumor 15
Focused panel assesses common somatic variants in solid tumors
Focusing on identifying inherited cardiac conditions
TruSight Inherited Disease
Focusing on severe, recessive pediatric onset diseases
- Custom Content
Build your custom panel in DesignStudio
TruSeq Custom Amplicon
Discontinued TruSight products and recommended replacements are shown below:
For Research Use Only. Not for use in diagnostic procedures.
Note regarding biomarker patents and other patents unique to specific uses of products.
Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.